Aridis Pharmaceuticals Stock Profit Margin
ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Aridis Pharmaceuticals fundamentals help investors to digest information that contributes to Aridis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aridis Pink Sheet. The fundamental analysis module provides a way to measure Aridis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aridis Pharmaceuticals pink sheet.
Aridis |
Aridis Pharmaceuticals Company Profit Margin Analysis
Aridis Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Aridis Pharmaceuticals has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
All Next | Launch Module |
Aridis Fundamentals
Return On Asset | -1.08 | ||||
Operating Margin | (9.58) % | ||||
Current Valuation | 12.11 M | ||||
Shares Outstanding | 36.21 M | ||||
Shares Owned By Insiders | 31.53 % | ||||
Shares Owned By Institutions | 11.60 % | ||||
Number Of Shares Shorted | 2 M | ||||
Price To Earning | (1.41) X | ||||
Price To Book | 5.40 X | ||||
Price To Sales | 7.33 X | ||||
Gross Profit | (22.61 M) | ||||
EBITDA | (29.51 M) | ||||
Net Income | (30.37 M) | ||||
Cash And Equivalents | 6.32 M | ||||
Cash Per Share | 0.36 X | ||||
Total Debt | 6.13 M | ||||
Debt To Equity | (0.18) % | ||||
Current Ratio | 0.41 X | ||||
Book Value Per Share | (0.77) X | ||||
Cash Flow From Operations | (29.13 M) | ||||
Short Ratio | 0.22 X | ||||
Earnings Per Share | (1.15) X | ||||
Price To Earnings To Growth | (0.02) X | ||||
Target Price | 10.0 | ||||
Number Of Employees | 37 | ||||
Beta | 0.78 | ||||
Market Capitalization | 13.24 M | ||||
Total Asset | 14.7 M | ||||
Retained Earnings | (195.67 M) | ||||
Working Capital | (25.27 M) | ||||
Current Asset | 27.39 M | ||||
Current Liabilities | 3.06 M | ||||
Z Score | -26.03 | ||||
Net Asset | 14.7 M |
About Aridis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aridis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |